The first case settled under controversial new compensation rules for serious injuries has seen an NHS trust forced to nearly triple its payout to a 10-year-old girl left with cerebral palsy from £3.8m to £9.3m.
The case, involving East Lancashire Hospitals NHS trust, will send fresh shockwaves through the NHS and insurance companies, which have been braced for big increases in claims since the new “Ogden” formula was announced last month.
Despite intensive lobbying, the new rules came into force this week, and immediately resulted in a dramatic escalation in one payout. As recently as January, it was agreed that the 10-year-old would receive a lump sum capitalised at £3.77m, but this will now be increased to £9.29m.
Her solicitor, Leonie Millard of Forbes Solicitors in Accrington, said: “The benefit for the claimant from the new -0.75% discount rate, is immense. It vastly improves the long-term future financial ability to meet her needs for the rest of her life, which is expected to be long. Her parents are comforted to know that there is funding to ensure that her needs are properly met when they are no longer around.”
Until now the Ogden formula for paying out compensation assumed that the claimant could earn 2.5% interest a year on a lump-sum payment. But under the new rules, the rate is assumed to be -0.75%.
In documents published after the budget, it emerged the government’s finances will take a near-£6bn hit as a result of the increased bill faced by the NHS and other parts of the public sector as a result of the changes made to the way compensation awards will now be calculated.
The Office for Budget Responsibility said the government would be setting aside an extra £1.2bn a year to meet the expected costs to the public sector – and it would push up car insurance premiums by about 10%.
The Association of British Insurers said it was “crazy” that up to 36m insurance policies could be affected in what it alleged would be “over-compensating” a few thousand claimants a year.
It is estimated that the cost of the average car insurance policy could increase by £60 a year, but for younger and older drivers, the increase will be higher. Comparison site comparethemarket.com said the average price for drivers aged 17 to 20 will rise by £115 to £1,650. The total increase in premiums paid by all motorists is expected to reach £2bn.
Direct Line, one of Britain’s biggest insurers, has already blamed a £217m slump in profits on the new Ogden rate, as it pencilled in bills for some individual cases doubling from £10m to £20m.
The lord chancellor, Liz Truss, has said there will be consultation on the new rules, but the insurance industry says it has yet to be told the shape of any reforms that might be forthcoming.
The ABI said: “The first wave of impacts on insurance costs are already being felt. A number of insurers have already publicly confirmed that premiums are going up as a result of the decision in February to cut the discount rate.”
Huw Evans, director general of the ABI, said: “The massive rise in insurers’ claims costs, which makes premium rises for millions of customers inevitable, results from a wholly avoidable decision by the lord chancellor. It was based on pressure from claimant lawyers, poor legal advice and an outdated formula that does not reflect the choices available today for a prudent claimant. With the public purse hit by £6bn, the government consultation cannot come soon enough.”
But Michael Redfern, the QC who was counsel for the 10-year-old girl, known only as “LMS”, said: “The large increase in lump-sum awards is offset by lack of return on lump-sum low-risk investment and the ability to keep pace with inflation.
“We welcome the new discount rate, the first change in 17 years, which addresses the actual lack of meaningful return on safe lump-sum investment opportunities. The only person to benefit from the new discount rate is the claimant. It has no impact on legal costs.”
If you’re looking for alternative methods to naturally heal your type 2 diabetes for life, then there’s a highly effective method for you to try.
The actual statistics for type 2 diabetes are shocking.
Worldwide there are now 347 million people who now have diabetes. (1)
Of these same people 90% of them suffer with type 2 diabetes. (1) The World Health Organisation projects that diabetes deaths will increase by two thirds between 2008 and 2030 (1).
In the United States, diabetes affects 25.8 million people of all ages which is 8.3% of the U.S. population (2).
Shocking as these figures are, it is also the other diseases and health issues that can affect many diabetics that is also a great cause for concern.
Did you know that diabetes is the leading cause of kidney failure, non-traumatic lower-limb amputations, and new cases of blindness among adults in the United States, as well as a major cause of heart disease and strokes. (2)
So what exactly is type 2 diabetes?
Type 2 diabetes or ‘adult diabetes’ as it used to be call (not so now as more and more children are now suffering from it) is a metabolic disorder where the body becomes insulin resistant and is characterized by a high level of glucose in the blood.
Put simply the hormone insulin, which is produced by the pancreas, is required to transport the sugars in our blood (that we get from what we eat) into your body’s cells where they can then be utilised.
The problem with type 2 diabetes happens when the body’s cells begin to literally ‘resist’ the insulin hormone which is transporting the sugars.
This means the sugar continues to circulate around the blood instead of going straight into the body’s cells and so the pancreas produces even more insulin in an effort to transport the sugar (glucose) out of the blood and into the cells of the body, thus stressing the pancreas.
Over a long period of time this will have a debilitating effect on the pancreas due to it being stressed by the over-production of insulin.
This will often result in less and less insulin being produced by the pancreas and so the need for more drugs/medical intervention.
The other type of diabetes (type 1) differs from type 2 in that the insulin producing cells of the pancreas are destroy by the body’s own immune system (known as autoimmune disease).
As yet, there is no known cure for the Type 1 diabetes, where patients need to take insulin via medication, though a healthy lifestyle, including diet, can certainly help you improve Type 1 diabetes.
Why do people get type 2 diabetes?
Within the mainstream medical profession, it is understood that there is no one single cause of type 2 diabetes and it is thought that a person’s chance of developing this disease is linked to several factors, which include:
An individual’s genetic predisposition
Environmental factors, such as exposure to endocrine disrupting chemicals
Lifestyle factors, such as being overweight/obese, lack of exercise and poor diet
No doubt factors, such as genetics and the others listed do play a part in ‘deciding’ what diseases may affect you personally.
Yet people with type 2 diabetes have completely healed their condition with the help of a high-carbohydrate, plant-based diet.
So what exactly has a standard diet got to do with type 2 diabetes?
Processed food, FAT and large amounts of it!
Many health professionals outside of the mainstream now advocate around 10% fat or less to be truly healthy such as Dr John McDougall, Dr Neal Barnard, and Dr Michael Klaper to name just a few.
And the reason is because they recognize that the modern western diet as it is now has way too much fat, including saturated animal fat, which is well known for its many negative health effects.
Insulin and high fat intake do not go together well!
Consuming too much fat (both animal and plant-based fat) and over loading the body with it can lead to also sorts of health issues.
One of these is when fat begins to interfere with the process of sugar metabolism and brings on the disease we know as type 2 diabetes.
With a sustained high fat intake the cells of the body begin to struggle with the delivery of the sugars via the transport medium we know as the hormone (insulin).
With the excess fat coating the cells and thus impairing this hugely important process the disease we know as type 2 diabetes begins.
Many studies have been conducted over the years that show a high carbohydrate, low fat, plant-based diet can make a huge positive impact on the health of people who are suffering with Type 2 diabetes.
For instance, studies carried out by the University of Kentucky Medical School reported that as many as two-thirds of diabetics were able to discontinue with the use of insulin and almost all of them stopped oral medication (3).
Another study found how a low fat vegan diet improves glycemic control in individuals with Type 2 diabetes. (4)
Studies tend to use low fat vegetarian diets to carry out their testing, but you can do even better than this diet and that is switching to a low fat vegan plan with lots of raw foods on the menu.
For example, several of our clients and followers have actually reversed their type 2 diabetes completely by switching to a fruit based raw or mostly raw food lifestyle.
Bibi Zambrano came off her diabetes medication within 2 weeks after switching to a high fruit mostly raw food diet and has been off it since. She’s also lost excess weight that she was carrying and healed many other health issues that she had.
She shares her story in this video:
[embedded content]
What can you do if you already have type 2 diabetes?
With the understanding that diet plays a crucial role in whether or not you get Type 2 diabetes, the need for a high carbohydrate, low fat and plant-based diet becomes self-evident.
As well as helping you balance Type 2 diabetes, it will also help you shed excess weight naturally, maintain a slim figure for life, have more energy and a much greater inner connection.
Making a transition to this way of eating doesn’t have to be hard either — you can simply begin to replace your old food with new and healthy alternatives.
Once you’ve started experiencing all these amazing changes, you’ll wonder how you ever lived without them!
About the author: Yulia Tarbath is a Certified Holistic Nutritionist at Rawsomehealthy, author, parent and international speaker with nearly 8 years of experience on a raw foods, vegan lifestyle. She’s passionate about supporting you in cleansing and healing your body the sweet way, as well as achieving the shape and health of your dreams.
Get started on a high-carbohydrate plant-based diet today by signing up to this FREE 5-day raw food menu plan!
Kiehm TG, Anderson JW, Ward K. Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men. Am J Clin Nutr. 1976 Aug;29(8):895-9.
When you think of feeling better or fighting off sickness, the first thing that might pop into your mind is, “I’ll take some vitamin C”. You drink some orange juice, maybe an Emergen-C packet, or even take a few tablets of bottled vitamin C in order to chase away the symptoms of an impending cold, flu, or feeling of general fatigue and malaise. Taking between 50-2000 mg during a few days leaves you believing that, “Wow, that vitamin C really helped kick that sick feeling to the curb!”
Vitamin C, whether taken in low or high doses, coupled with its reported health benefiting properties, has been quite controversial for the past several decades and according to the University of California Berkley, no other vitamin has been so extensively researched since 1932. And as of today, despite all the studies, vitamin C still remains a mystery with a divided consensus. The question remains, does it help?
Believe or not, there are two schools of thought regarding water soluble vitamin C also known as L-ascorbic acid or ascorbate. Humans require a regular intake of vitamin C (30-95 mg daily depending on age) because our bodies do not produce nor store this vitamin, however excrete it very quickly.[1] Vitamin C is imperative for maintenance of all the body tissues, proper growth, and wound healing.
New data about the positive effects of vitamin C on the immune system have been introduced in the last several years.[2] Immune cells contain active vitamin C transporter molecules within their membranes that actively pump the vitamin into the cells when more vitamin C is necessary[3], especially phagocytes and T-cells. According to the National Institutes of Health (NIH), a vitamin C deficiency results in a reduced resistance against certain pathogens, while a higher supply enhances several immune system parameters.[4]
On the other side, a Cochrane Collaboration review has concluded that vitamin C has shown no consistent effect on the duration or severity of helping the common cold symptoms after the initial onset.[5] Although, evidence suggests that it could be justified in people exposed to brief periods of severe physical exercise or cold environments.[6] Whereas, Dr. H.K. Bakhru states, “vitamin C helps prevent and cure the common cold and protects an individual against infections”.[7] It is evident that one community believes it does not help much with the prevention and dissipation of cold and flu symptoms and an increase of immunological factors while the other faction believes it does.
A recent controlled trial study showed that vitamin C deficiency has been linked with frequency and duration of colds coupled with immune system defects, and that there are measurable health advantages associated with vitamin C supplementation.[8] Taking into account that if vitamin C introduced into the body will increase immunity, the next question is which form of vitamin C should be taken?
Here is the secret: few people differentiate between the natural vitamin C which you find in fruits and vegetables (citrus, acerola cherries, greens), and synthetic ascorbic vitamin C present in most energizing drinks, vitamin packets, and vitamin C Bottles that you can buy at your local pharmacy or health food store. Because the two are usually marketed side by side as being one in the same, most people are led to believe that if the label says all natural vitamin C, it must be food based, therefore real and wholesome. However, there is a difference. As O. Hofmleker states,”in its natural form vitamin C has a different design than the synthetic vitamin. The natural vitamin C molecule never occurs in isolated form, but rather accompanied by complex nutrients which apparently are essential for vitamin C’s bioactivity. The synthetic ascorbate however, appears in an isolated form, often in overly high concentrations which the human body hasn’t evolved to properly utilize. Human biology has never evolved to accept synthetic vitamins”.[9]
Synthetic vitamin C was introduced in the 1930’s into the market causing all the rage. However, with its inception it pushed the focus of natural wholesome vitamin C found in foods to the back shelf making it a thing of the past. Since then the new trend has been this synthetic ascorbic acid reportedly being linked to all sorts of health benefits.[[10]–[11]–[12] ] It was also believed to be more readily available year round instead of its natural whole food counterpart. The interesting thing is after so many decades and numerous studies conducted, it has actually been shown that ascorbic acid causes potential damage to health. A recent study on vitamin C (Am J Clin Nutr; Jan 2008) showed adults taking the synthetic version had serious side effects and significant adverse effects on the antioxidant system. Dr. Victor Herbert, professor of medicine at the Mount Sinai School of Medicine in New York has said, “vitamin C in supplement forms mobilizes harmless ferric iron stored in the body and converts it to harmful ferrous iron, which induces damage to the heart and other organs. In addition, unlike the vitamin C naturally present in foods like orange juice, vitamin C as a supplement is not an antioxidant.”[13]
So in order to take the most optimal vitamin C, you should kick the synthetic vitamin C (which is usually ascorbic acid derived from genetically modified corn) and start ingesting either real fruits and vegetables or food-based vitamin C supplements with the highest amount of real vitamin C and bio-available nutrients. Ideally, vitamin C should be ingested in its natural wholesome form in order to give its all encompassing health benefiting properties in the areas of cardiovascular and immunological health.[14] According to NIH, those fruits are fresh, raw cantaloupes, citrus fruits, kiwis, mangos, papayas, pineapples, strawberries, raspberries, blueberries, watermelon, and cranberries.[15] In addition, peppers, kale, broccoli and peas are also great options.
Do yourself a favor and introduce natural vitamin C in the form of fruits and vegetables to your daily diet. It can be in the form of fresh squeezed juice, smoothies, or as fruit and vegetable snacks throughout the day. Your body will thank you. Not only will you be supplying yourself with a daily dose of natural vitamin C required for the proper running of your body and its systems, but you will be able to forgo the bottles, powder packets, and drinks filled with a synthetic vitamin that your body was not engineered to consume. The real vitamin C is in fruits and vegetables. Nothing else comes close to that nor can it mimic its intrinsic healing properties. Introduce the real vitamin C into your daily eating habits!
Interesting fact: Vitamin C is the most widely researched nutrient on the Internet.
[1] Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003 Feb;22(1):18-35.
[2] Pavlovic V. A short overview of vitamin C and selected cells of the immune system. Cent. Eur. J. Med. 2010 October;8(1):1-10.
[3] Strohle A, Wolters M, Hahn A. Micronutrients at the interface between inflammation and infection–ascorbic acid and calciferol: part 1, general overview with a focus on ascorbic acid. Inflamm Allergy Drug Targets. 2011 Feb;10(1):54-63.
[4] Ströhle A, Hahn A. Viatmin C and immune function. Med Monatsschr Pharm. 2009 Feb;32(2):49-54.[PubMed abstract]
[5] Douglas RM, Hemilä H. Vitamin C for preventing and treating the common cold. PLoS Med 2005;2:e168. [PubMed abstract]
5 Douglas RM, Hemilä H, Chalker E, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2007;(3):CD000980. [PubMed abstract]
[7] Bakhru H.K., The Complete Handbook of Nature Cure (Mumbai: Jaico Publishing House, 2014), 101.
[8] Johnston CS, Barkyoumb GM, Schumacher SS. Vitamin C supplementation slightly improves physical activity levels and reduces cold incidence in men with marginal vitamin C status: a randomized controlled trial. Nutrients. 2014 Jul;6(7):2572-83.
[9] Ori Hofmleker, “Vitamin Poisioning: Are We Destroying Our Health with Hi-Potency Synthetic Vitamins?”, https://www.organicconsumers.org/news/vitamin-poisoning-are-we-destroying-our-health-hi-potency-synthetic-vitamins, (accessed Dec. 21, 2016)
[10] Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. J Hypertens. 2000 Apr;18(4):411-5.
[11]Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, et al. Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants. Am J Respir Crit Care Med. 2002 Sep 1;166(5):703-9.
[12]Afkhami-Ardekani M, Shojaoddiny-Ardekani A. Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients. Indian J Med Res. 2007 Nov;126(5):471-4.
[13] Jane E.Brody, “Taking to much vitamin C can be dangerous, study finds”, April 9, 1998, http://www.nytimes.com/1998/04/09/us/taking-too-much-vitamin-c-can-be-dangerous-study-finds.html (accessed Dec.21, 2016).
[14]Asim K. Duttaroy, Aud Jørgensen, “Effects of kiwi fruit consumption on platelet aggregation and plasma lipids in healthy human volunteers”, Platelets (2004) 15(5), 287–292, doi: 10.1080/09537100410001710290.
It was the case of the superstar surgeon, the prestigious Swedish institute and the ill-fated windpipe transplants that escalated into allegations of misconduct, dismissal and a criminal investigation.
Now, a leading British university has launched an inquiry into its own links with the endeavours of Paolo Macchiarini, the surgeon at the centre of the trachea operations following which six patients died.
The surgery, pioneered five years ago with the world’s first synthetic windpipe transplant at Stockholm’s prestigious Karolinska Institute, appeared to mark the beginning of an era in which artificial organs could be created from scratch by scientists and seamlessly integrated into the human body.
However, the remarkable success story began to unravel. In March, the Italian surgeon was dismissed from the Karolinska Institute amid an unfolding medical scandal and Swedish prosecutors are conducting a criminal investigation.
Now, in a case that has sent ripples across the scientific world, University College London has launched an inquiry into links with the controversial surgeon.
The latest investigation will probe its relationship with regenerative medicine research that may have taken place at Karolinska. Several of its senior scientists contributed to the procedures pioneered by Macchiarini, in which donor or synthetic tracheas were seeded with the patient’s own stem cells with the aim of creating new, functioning organs.
There is no suggestion that the UCL academics are implicated in any misconduct.
The regenerative surgery initially appeared to have gone well, and was described as successful in high profile journal articles, but it later emerged that six of the eight patients to receive synthetic tracheas had died, while another remains in intensive care. Karolinska’s vice chancellor resigned and its entire board were sacked earlier this year after they continued to back the Italian surgeon despite warnings of clinical and scientific misconduct.
Karl-Henrik Grinnemo, a surgeon who worked alongside Macchiarini at Karolinska, said of his former colleague that there was always a sense of emergency that led to him bypassing standard ethical safeguards in international collaborations.
“It was ‘They’re severely ill and they will die very soon and … we can’t wait to get the permissions from the regulators’,” he said. “Everything was always in a hurry when it came to Paolo Macchiarini.”
Alexander Seifalian, a former UCL professor of biomaterials, created the first synthetic trachea to be transplanted into a patient. The 36-year old Eritrean man, Andemariam Beyene, had been suffering from advanced tracheal cancer and died two-and-a-half years after the transplant. Seifalian was dismissed from UCL in July, after a tribunal in an unrelated case found that he had dishonestly obtained £24,000 from an overseas student.
Seifalian, who had developed a polymer material to make artificial ears and noses, said he agreed to produce a synthetic trachea in just 10 days after being approached by Macchiarini, who told him his patient had only two weeks to live. In a 2013 TED talk, Seifalian recalled asking his PhD student to obtain sheep and pig tracheas from the butchers, because they did not know what the organ looked like.
“I said ‘Go on Google and type in trachea’,” he recalled in the talk.
According to Grinnemo, who assisted in the operation, “none of the [Stockholm] patients needed an operation that urgently. They would have survived even years. You could have waited for the regulators to look at the material and the cells.”
Grinnemo later concluded that the entire synthetic trachea concept was doomed to fail because the plastic would inevitably become infected as it was exposed to bacteria and viruses with each breath, adding that he now views the synthetic transplant as a “death tube”.
While the material was approved as safe for clinical use, the actual trachea was never formally assessed as a new medical device, meaning this risk was not fully considered.
Seifalian told the Guardian: “At the time he came to our laboratory and he said this is the only chance of survival for this patient … Yes if we had a longer time, we would have made a better scaffold. Everything was in a rush.”
Seifalian later made a synthetic trachea for a 20-year-old British woman, Keziah Shorten, who was treated at University College Hospital London in 2011.
Martin Birchall, a UCL professor of laryngology who coordinated the surgery, said that on the back of positive reports from Karolinska, the team were given approval to perform a synthetic trachea transplant under compassionate use rules. The surgery allowed Shorten, who had been in a critical condition in intensive care following cancer treatment, to return home for a brief period, but she died three months later.
“At the time it was the rational thing to do,” said Birchall. “We wouldn’t do it again now.”
Birchall had collaborated with Macchiarini on a transplant carried out in a Spanish clinic in 2008.
He too recalls a sense of urgency when helping to prepare the donor trachea that had been stripped of its cells and re-populated with stem cells taken from the bone marrow of the 30-year-old patient, Claudia Castillo.
Birchall, then at Bristol University, was given permission by the Human Tissue Authority to prepare the cells in a veterinary laboratory, that was not licensed for clinical applications. In a 2008 letter the HTA said it would not stand in the way of what “could in this particular case be life-saving therapy” for a “carcinoma patient”.
The surgery was required because one branch of Castillo’s windpipe (the bronchus) had been damaged by a TB infection. Her left lung was at risk of being surgically removed, but she was not at immediate risk of dying, according to the Barcelona clinic where she was treated.
Birchall told the Guardian that he believed the additional risk this carried was justified because “my firm belief was her life was in danger and we needed to move quickly”, adding that even so he would not have carried out the work without HTA approval.
There is no suggestion that the cells caused any health problems, but Castillo suffered extensive complications and ultimately had her lung removed earlier this year, raising questions about whether the risk was warranted.
In a statement, UCL said: “Following recent events at the Karolinska Institute in Sweden relating to some aspects of regenerative medicine research, UCL’s Vice Provost (Research) has instigated a special inquiry in order to establish the nature and scope of regenerative medicine research at UCL and to establish the nature of UCL’s relationship with regenerative medicine research that may have taken place at the Karolinska Institute.”
Macchiarini rejected claims that he misrepresented the clinical condition of patients to collaborators. Of the first synthetic transplant, he said: “All of us involved in Andemariam Beyene’s care wanted to give him the very best chance possible, and he and his family expressed their gratitude for the extra years we gave him.”
One morning when he was 12, Samuel Blaise decided to skip school with his best friend Cyril. Both boys hitched a ride across the French countryside, back to their small Normandy town. By noon, they were home unsupervised. “Let’s have a drink,” Cyril suggested. “We can try the whiskey, the one my father likes.”
They had a nip, and then another. “It tasted horrible,” Blaise recalls. “But something clicked. I suddenly felt relaxed and at peace. We polished it off and spent the afternoon lying down on the tiled floor. It felt like I was sleeping in cotton wool. I had discovered my drug.”
Soon Blaise started drinking on his own every night, raiding his parents’ cabinet for potent liqueurs. To avoid being found out, he would mix a “coffin” – a slug of every other bottle he could find mixed in a tall glass. He would sip it quietly while the rest of the family slept upstairs.
Blaise, who is now 46 and an entrepreneur in Paris, says that for decades, only booze could ease his “pathological anxiety”. In his late 30s, at the height of his addiction, he would down between one and two liters of strong beer, followed by a bottle of wine and servings of vodka or whiskey. Sometimes he would wake up in the street or in hospital after a blackout.
Finally, a doctor confronted him with enough force that Blaise believed him: he was a handful of years from death. Blaise tried AA, multiple medications, and three week detox programs. Nothing worked. He and his partner – they have two children together – knew something drastic needed to be done. So on Christmas Day 2011, Blaise sat down at his computer and started and started typing, looking for help.
Then, after scrolling through pages and pages, he found his holy grail: a medication called Baclofen.
The doctor who played guinea pig
Oliver Ameisen, a noted French cardiologist, also knew a thing or two about alcohol.
Ameisen was, from the outside, a wildly successful man. He had a private practice in Manhattan, had been awarded the Légion d’Honneur for his work and, to top it all, was a brilliant pianist. But the physician was also helplessly addicted to alcohol and regularly hospitalized after binges. Like Blaise, every single treatment had failed him.
His situation was desperate, but a thought kept nagging him. After reading a New York Times article describing how Baclofen eased the muscle spams of a cocaine addict, he developed a hunch that the drug – a relaxant typically used to treat patients with multiple sclerosis – might help him.
With nothing left to lose, he decided to turn himself into a guinea pig, reasoning that it was “more dignified to die during my own clinical experiment than it was to die of alcoholism”. In 2004, he started taking small, and then increasing doses of the drug. He was astonished when, a few weeks in, his cravings disappeared. He simply had no desire for a glass of wine anymore.
The Last Glass, the account of his miraculous recovery, came out 2008. Its publication turned him into something of an evangelist for Baclofen.
With more than five millions “problematic drinkers” in France (120 people die from alcohol-related diseases every day), it was only a matter of time before addicts found themselves frantically banging on their primary care doctors’ doors to get their hands on the treatment.
But it wasn’t that straightforward. The drug had to be prescribed off label (that is, not for its original medical use), which health authorities frowned at. To make matters worse, most doctors had never heard of it, and those who had were wary to recommend a treatment which could have severe side effects, including severe insomnia, drowsiness, depression, heightened anxiety and mood changes.
‘I didn’t care about side effects, I just wanted to be free from the booze’
Blaise, too, had come to believe Baclofen was his last chance after reading online testimonials. In a frenzy, he contacted doctors in Canada, Lyon and Paris in the hope of finding someone willing to prescribe him the drug. He finally found Bernard Granger, a psychiatrist and addiction expert turned true believer in the treatment’s efficacy. At the end of his tether, Blaise left a desperate message on his phone. “Please,” he said. “I would do anything to get help.”
A few days later, the two met and talked about the treatment, potential side effects and titration (the process of gradually adjusting the doses until optimal results are reached.) Blaise signed a waiver discharging Granger of any wrongdoing in the event of his own death.
I suddenly understood my addiction was over. I’ve been cured of my alcoholism ever since
On 7 January 2011, full of hope, he swallowed his first pills.
Blaise was, by his own account, not the perfect patient. Two weeks in, he was taking 340mg per day, way above the recommended dose (the French health safety agency allows for a maximum of 300mg, while most doctors in the UK prescribe less than 100mg).
At this stage, Blaise recalls, “ I didn’t care about secondary effects, I just wanted to be free from booze.” He knew that studies had shown very high doses are often necessary to produce a state of complete indifference to alcohol. He also knew there was a significant relationship between the amount of alcohol consumed before treatment and the maximal dose needed by patients to obtain results.
In a 2008 French study, 88% of patients reported “at least one undesirable side effect that could possibly be attributable to Baclofen”, some so unbearable that patients had to stop treatment.
As it turned out, the side effects experienced by Blaise were brutal. He developed both psychotic and manic behaviors, couldn’t sleep, had night sweats, muscle spams, and his sense of taste and hearing changed. He found himself talking to God and thought he understood the world’s great mysteries (in his delusion, he says, “I was sure I had finally cracked the number Pi in its entirety.”) Granger promptly put him on anti-psychotics, which induced a deep depression. He switched to anti-depressants, which finally stabilized him.
On 17 January, still drinking, Blaise got arrested for disorderly conduct and cocaine possession. He also had dozens of Baclofen pills on him, which police officers mistook for drugs. “They didn’t believe a word I said,” he said, still amused by the incident. “They were laughing hard when I begged them for the pills. I was kept in jail for 33 hours.”
But two weeks later, while walking the streets at 4am, he felt a sense of physical liberation comes crashing over him. “It lasted for a few seconds. And I suddenly understood my addiction was over. I’ve been cured of my alcoholism ever since.”
For the entirety of 2012, he stayed stone-cold sober. Nowadays, he says, he will “drink a glass of good wine or two when I have people over. But I can’t drink more than that. I just don’t crave it anymore.”
Clinical trials are in: Baclofen (kind of) works
In the years that followed Ameisen’s discovery, medical authorities in France were put under enormous pressure to allow doctors to temporarily prescribe Baclofen for alcoholism while clinal studies were still underway. Associations of former addicts (which Blaise is now heavily involved in) lobbied hard, but it remained a tough sell – until now.
One of their greatest victories came last week, when a study involving a significant number of patients partially confirmed its efficacy.
Bacloville, the first study led by Philippe Jaury at the Paris Descartes University, administered high doses (the average was 160mg/day) to 320 volunteers aged 18-65 for a year while still allowing them to drink. 56.8% of patients either became abstinent or significantly decreased their to normal consumption levels. The same results were observed in only 36.5% of patients who were given placebos.
A second study, led by Michel Reynaud at the Paul Brousse hospital, had less impressive results. It tracked consumption in 320 patients who had already been abstinent for 20 weeks and ingested an average of 153 mg/day. 11.9% of those taking Baclofen remained alcohol-free, while 10.5% of those on placebo did.
Anne Lingford-Hughes, professor of addiction biology at London’s Imperial College, attended the conference where the results were released. She thinks more data is needed to be truly conclusive on the Bacloville study but so far clinal trials, she says, support the idea that the more severely dependent on alcohol you are, the more likely you are to get benefits from Baclofen.
But, she adds, there’s a lot of concern in medical communities when it comes to giving it to people who drink heavily because of the drug/alcohol interaction, as well as potential overdoses. None of her colleagues in the UK, she says, would prescribe as high a dosage as it is currently prescribed in France.
Not one drop: the problem with total abstinence
The success rate as reported by the Bacloville study is staggering – much higher than rehab centers or even spontaneous rates of recovery (a quarter of people addicted to alcohol eventually recover on their own, while a lot of rehab rates do not even reach that number).
But Dr Jaury, who led the study, says that the idea of such a cure prompted a swift reaction from those with a vested interested in seeing it fail.
According to him, the backlash from the detox industry was swift and ferocious. There was also pushback from some members of Alcoholic Anonymous (AA), which he says promotes a culture of total abstinence. Jaury thinks it’s a shame: “I’ve had patients who were in AA but still secretly took substitution drugs such as methadone or Subutex. They kept it a secret, out of shame and because they don’t want to be excluded from the group.”
Blaise, who still takes Baclofen six years on, agrees and calls the abstinence model “idiotic”.
“For AA,” he says, “the illness is incurable. So I would now have to go to a meeting and say ‘hello, my name is Samuel and I am an alcoholic’. But I am a former alcoholic, not an abstinent one.”
He adds: “They function like a church. Their fourth step commands members to submit to a higher being, but suddenly, scientists arrive with a medication and rationally explain that a biological issue can be fixed. Suddenly, you don’t need abstinence, you don’t need a higher being. The very basis of the church comes crashing with it.”
Blaise says that while he greatly respects members, he has heard a sentiment akin to “you don’t deserve to be cured” from the AA crowd. This makes sense, he says, because to be in a constant state of craving is unthinkably hard. “You need to be at war with yourself to remain sober, minute after minute, day after day. AA people spend years, or even decades before finally reach a state of indifference towards booze, whereas those of us who take Baclofen have to fight a mere few weeks.”
As a result, Blaise says some members believe people like him have merely replaced one drug with another. (When contacted directly, the French chapter of AA says it remains completely neutral on the subject – the organisation “has a rule to never issue an opinion on topics outside our movement”.)
But what about those who can keep their lives together but drink a bit too much?
Sylvie Imbert, a 59-year-old retired computer engineer who founded the French Baclofen Association, didn’t hit rock bottom as Blaise did. Instead, as she was nearing 50, she simply became uncomfortable with the amount she was drinking.
In 2009, she took matters in her own hands and made the two hour long trip from Toulouse to Spain, where Baclofen is sold over the counter. She began taking the drug without medical supervision, and promised herself she would stop should the side effects prove too much (a process she doesn’t recommend). When she reached 120mg a day, her cravings vanished.
She now spends her time spreading the word and counseling people on her website’s forum. “We have up to 2,000 visits a day,” she says. A growing number of her readers are interested in Baclofen for other addictive behaviors, bulimia and gambling among them (a small 2007 trial on seven patients showed that Baclofen reduced binge eating frequency).
Caution before zeal? The novelist who lost her mind to it
Sylvie Imbert and Samuel Blaise both had happy endings to their story. For others, Baclofen was devastating.
In 2008, a British PR executive called Anna Sargent bought Baclofen online to finally stop drinking. She suffered severe side effects and panic attacks when she stopped taking it, and killed herself soon afterwards. Her parents blamed the drug, and said at the time that she “couldn’t face more of these terrible effects of feeling anxious and suicidal”.
The story of Alix de Saint-André, a renowned Parisian novelist, is another case in point.
When Saint-André read about Baclofen, she decided to try the drug “as an adventure” in order to give up smoking. At the time she was chain-smoking three packs a day and had tried to quit many times without success.
Under close supervision (a physician friend of hers who admired Ameisein’s work agreed to give her a prescription), she holed herself in her country home during Christmas break to start the process, always making sure to stay within the recommended dosage.
This was 2008, and while the protocol was relatively new, Saint-André was comforted by Ameisen’s assurance that Baclofen’s side effects were “as hurtful as drinking a glass of water”.
Soon, however, she stopped sleeping and lost her appetite (she also started to write, and was delighted by her sudden rush of inspiration). A few days later, things took a turn for the worse. She had hallucinations, paced her bedroom endlessly, and found herself talking to saints and dead scholars.
A friend of hers quickly became alarmed and forced her to check in a psychiatric hospital, where she stayed for four hellish weeks. In her memoir L’Angoisse De La Page Folle, Saint-André details how her full recovery would take a whole year, and included weekly sessions with a psychiatrist as well as anti-psychotics and anti-depressants.
Her experience left her skeptical of a drug so many called “life saving”. As she researched what had happened to her, she found another case of Baclofen-induced psychosis in medical literature, which spurred her to alert the media about it (they took little notice, she says). Saint-André worries that cases similar to hers are ignored by overenthusiastic doctors – and the thought of patients self-medicating with no professional supervision mortifies her.
French doctors, she says, are quick to fight back with a utilitarian reasoning: if Baclofen can help half of the 120 people a day who die from alcohol-related diseases while only a tiny percentage experience severe side effects, there’s no question it should be used. “I’ve had doctors keen to remind me that some people died when the first vaccines were being tested on them,” she says.
After the publication of her book, Saint-André says she was contacted by readers with similar stories. One man told her about how his wife had been prescribed Baclofen by a dermatologist to, of all things, lose weight.
Three weeks in, she started to suffer from paranoid delusions. Shortly thereafter, she threw herself out of a window.
Repeat it like a mantra: in addiction, no size fits all
As addiction experts are keen to remind us, there isn’t “one size fits all” treatment to cure patients – something of a truism within the addiction field.
Marc Lewis, a neuroscientist and former addict who wrote Memoirs of an Addicted Brain, is keen to highlight that a lot of different approaches can be therapeutic. “The therapy has to fit the person, not the substance [they’re taking].”
But first, he says, physicians have to be trained to identify if a treatment is working, and most importantly trained to understand addiction (Lewis is keen to refer to addiction a “cognitive habit”, as opposed to a chronic disease. A habit can learned, and therefore can be unlearned.)
Medication might have saved people like Ameisen, but for others, AA, talking therapy, mindfulness, exercise and rehab treatment (or a combination) might work. “People recover in very different ways,” Lewis says. “A lot of patients don’t respond to medication. There’s a lot of people with serious sex addiction, eating addiction, serious compulsive gambling problems … and medication can’t do anything for them.”
Whether Baclofen will eventually become a staple for addictions other than alcoholism remains unclear. But armed with the clinical trial results published this September, the pharmaceutical company Ethypharm has already announced its intention to push for a full licensing of the drug specifically to treat alcoholism as soon as the full results of the Bacloville study are published.
The race for a cure doesn’t stop here. In the US, the pharmaceutical company Indivior has already licensed Placarbil, a variant of the Baclofen molecule with more efficient pharmaceutical proprieties and improved absorption rates. Trials are under way, and results are expected at the end of the year.
If the findings are encouraging, a similar controversy than the one currently unfolding in France will be sure to hit the US with some force.
Provided the scope of the Ebola outbreak unfolding in Western Africa, it seems possible that a case will at some point emerge in the U.S.
We could even see an isolated cluster of infections in an American city.
Thinking about the nature of the Ebola virus, and the health-related infrastructure we have to fight its spread, the diagnosis of some circumstances on American soil shouldn’t be reason to panic. We have a plethora of equipment and public overall health practices to readily combat its spread. Nevertheless since the virus is so harmful, and feared, its arrival in America would likely to trigger a robust response from our public health establishment.
For most Americans, it might be the 1st time they glimpse the resources that our government has staked out more than the last decade, as preparation for public well being emergencies like a pandemic flu, or even bioterrorism. Some of these authorities are wholly necessary. Other folks will demonstrate controversial and worthy of closer scrutiny.
Chief between them are authority maintained by the Centers for Illness Control to quarantine Americans suspected of possessing a unsafe, communicable illness. In some cases, this consists of the power to isolate men and women, and hold a healthful person against his will. The CDC’s quarantine authority has been strengthened in recent many years. But we haven’t had sufficient debate about how to stability person rights towards public wellness in these circumstances. And when quarantine is even successful. We ought to revisit these problems ahead of we find ourselves invoking these resources.
What will come about if Ebola arrives in America?
First, there will be a good deal of misplaced panic. But there is no cause for most Americans to worry of Ebola’s wider spread. Although Ebola is extremely infectious, it is not quite contagious.
It is extremely infectious because someone stricken with Ebola is extremely very likely to get sick (and harbors a whole lot of virus particles that they can readily transmit to yet another man or woman, offered the correct circumstances). But the virus itself is fragile, and does not simply spread. So it is not extremely contagious. In quick, Ebola is tougher to contract than a lot of other viruses.
The Ebola virus can only be spread by direct get in touch with (via broken skin or mucous membranes) with the blood, or other bodily fluids or secretions (stool, urine, saliva) of contaminated individuals. Infection can also take place if the broken skin of a healthful man or woman comes into speak to with environments that have become contaminated with an Ebola patient’s infectious fluids (such as soiled clothing).
In addition, individuals generally only grow to be contagious – and can spread the virus — as soon as they begin contracting signs and symptoms. Prior to the onset of symptoms, it is usually harder to spread the virus. But the onset of signs is usually quite serious. So it’s simple to understand that a person is sick. In addition, stricken men and women are significantly less likely to travel about – and spread the virus — offered their debilitated condition.
All of these elements make control of the infection possible. If isolated instances emerge in the U.S., our public wellness apparatus ought to be able to readily incorporate its spread.
However it’s very plausible that a case of Ebola could soon be diagnosed in the U.S.. For a single factor, the virus has a extended incubation period, up to 3 weeks. So an contaminated personal could travel abroad and contract signs and symptoms only properly following arriving at their destination.
Moreover, the identical aspect that is fueling its spread in Africa makes it a lot more likely that Ebola travels abroad. The African outbreak has occurred in urban areas. In the previous, outbreaks have been confined to rural communities, making it simpler to contain. The emergence of Ebola in urban settings has manufactured management harder, and put the virus in closer proximity to individuals who may possibly contract it and unwittingly get on an airplane.
If Ebola appears in the U.S., we have a robust public wellness infrastructure to contain its spread. In the previous decade, five individuals have entered the U.S. with Lassa fever and Marburg, two viral hemorrhagic fevers that are related to Ebola. This includes a situation in March of a Minnesota man diagnosed with Lassa fever right after traveling to West Africa. No a single else contracted the conditions as a outcome of these 5 circumstances.
But provided the deadly nature of the Ebola virus, and the common be concerned it is most likely to engender, a single can anticipate the CDC and well being authorities to pull out all the stops. The response could include invocation of the CDC’s evolving quarantine authorities.
These federal powers comprise a set of guidelines that gives CDC sweeping authority to hold and isolate Americans in a public well being emergency. These authorities haven’t been fully updated in decades. They’ve only been amended in piecemeal style to deal with contemporary threats like SARS and MERS. In advance of what may be a very public test of these powers, the collected scheme deserves closer scrutiny.
Even though there is broad consensus in the health-related neighborhood that principal PCI is the ideal remedy for heart assault patients when it can be delivered promptly, there is no agreement about the greatest accompanying drug routine, which normally entails a blend of antiplatelet and antithrombotic medication. The part of one particular antithrombotic, bivalirudin (Angiomax, The Medicines Firm) has been notably uncertain since it is far much more costly than its alternative, unfractionated heparin.
HEAT-PPCI was made to aid settle this dilemma. The investigators ran a large, sensible clinical trial that instantly randomized all main PCI sufferers at the Liverpool Heart and Chest Hospital in the Uk. The outcomes of the trial, which have been the topic of considerable debate when they had been presented at the American College of Cardiology meeting earlier this yr, have now been published in the Lancet, along with two editorials that tackle the controversies engendered by the trial.
one,829 sufferers have been randomized in the HEAT-PPCI trial to either heparin or bivalirudin. The final results did not show any advantage for bivalirudin. There was a considerable increase in the principal efficacy outcome– a composite of death, stroke, reinfarction, or unplanned target lesion revascularization– in the bivalirudin group compared with the heparin group (8.seven% versus 5.7%, RR one.53, CI 1.09-two.13, p=.01). There was no significant distinction in the incidence of major bleeding (3.5% versus three.one%, p-.59). The use of bailout GP IIb/IIIa inhibitors was comparable in both groups: 13% for bivalirudin and 15% for heparin.
The authors conclude that their trial “suggests that the use of heparin, rather than bivalirudin confers substantial benefit in the avoidance of major adverse occasions. This locating may well give an possibility, uncommon in modern day overall health care, to give improved outcomes at much diminished price. In our centre, routine use of heparin (rather than bivalirudin, which fees about 400 occasions as a lot) would reduce quick drug costs in our yearly 1000 PPCI instances by £500 000.”
In an accompanying editorial, Peter Berger and James Blankenship say that the distinction in findings among HEAT-PPCI and earlier trials can be explained by many factors, such as the lower use of GP IIb/IIIa inhibitor in conjunction with heparin in HEAT-PPCI, the use of greater doses of heparin in earlier studies, and the better use of radial access in HEAT-PPCI. The trial, they compose, “provides strong proof that bivalirudin alone compared with 70 U/kg of heparin alone (with infrequent bailout use of GP IIb/IIIA inhibitors in each arms), with radial entry for STEMI percutaneous coronary intervention, seems to be inferior to heparin as administered in this trial. Even if heparin alone had produced statistically similar outcomes to bivalirudin, it would have been a win for heparin. A drug that charges significantly less than a 400th of an additional that has comparable efficacy and safety ought be utilised preferentially.”
In a second editorial David Shaw dismisses the intense criticism from some prominent critics of the trial’s ethics based on the truth that trial participants did not offer informed consent till following they had been randomized. Rather, he writes, “HEAT-PPCI is not only an extraordinary achievement in medical analysis, but also in ethical study style. Far from becoming unethical, the research sets a large standard for consent in pragmatic trials.”
Delayed consent “was preferable to attempting to acquire consent from potentially incompetent individuals needing really urgent cardiac treatment… The use of delayed consent is specifically appropriate in pragmatic comparative effectiveness trials the place the two medicines below investigation are each used for licensed indications in problems of equipoise. In regimen clinical care, it would be completely standard for a physician to select either heparin or bilvalirudin with no involvement of the patient in the determination.”
The results of the trial also “mean that assets will not be wasted on bivalirudin, a much more pricey and much less successful treatment than heparin.” Shaw observes: “Unsurprisingly, significantly of the opposition to HEAT-PPCI has come from medical professionals with shut industry ties.”
Yesterday Dr. Mehmet Oz generally admitted just before a Senate subcommittee hearing that a lot of of the claims he can make about fat reduction dietary supplements are not primarily based in reality.
“I can not figure this out, Dr. Oz – I really don’t get why you need to have to say this stuff when you know it’s not real,” complained Senator Claire McCaskill in a hearing prior to the Senate subcommittee on Customer Safety, Item Security and Insurance. “When you have this incredible megaphone, why would you cheapen your display?”
Replied Oz: “I actually do personally believe in the things I talk about on the display. I passionately study them. I recognize that oftentimes they really don’t have the scientific muster to current as fact. However, I would give my audience the exact same suggestions I give my family members, and I have offered my family these merchandise.”
Senator Claire McCaskill chastised Dr. Oz yesterday for his enthusiastic coverage of untested excess weight loss dietary supplements. (Photograph: public domain)
The bodyweight loss products Dr. Oz is talking about are, of program, the numerous dietary supplements that have attained mega-success soon after a mention on his present, a phenomenon now recognized as “the Oz effect.”
And although he admits they’re “controversial,” he also argues that they’re a needed “crutch” for the two thirds of American grownups now classified as obese.
“If the only message I gave was to consume much less and move far more, which is the most crucial point people require to do, we wouldn’t be very successfully be tackling this challenge, because viewers know these actions and they nonetheless struggle,” he explained. “So we search for resources and crutches for quick-phrase help so folks can jump-start off their applications.”
Even more defending the role of his display, he adds: “I would rather have a conversation about these resources on my stage than in back alleys.”
So what are the fat loss supplements getting Dr. Oz into sizzling water? A rapid rundown:
one. Forskolin: In the hearings, McCaskill brings up Forskulin, reminding Oz that he called it “lightning in a bottle” and “a miracle flower” in an episode of his present this previous January.
What it actually is: A chemical located in the roots of the plant Plectranthus Barbatus that’s been utilised in traditional medication to treat higher blood pressure and heart disorders.
2. FBCx: Oz counters McCaskill with a defense of FBCx, “which is basically a fiber and we know that fiber when taken accurately is a really efficient fat reduction device.”
What it really is: A kind of fiber known as alpha-cyclodextrin that is been used to decrease cholesterol and bind triglycerides. The term FBCx is an abbreviation for “Fat Binding Complexer” and is generally just a branding term.
3. Raspberry Ketones: Dr. Oz has named it: “A number 1 miracle in a bottle to burn up your body fat.”
What it really is: A compound derived from red raspberries that may possibly help regulate adiponectin, a protein that impacts metabolic process.
four. Yakon Syrup: Dr. Oz has termed it “a metabolism game-changer.”
Creating in today’s edition of the BMJ, editor-in-chief Dr Fiona Godlee said it wanted to alert readers, the media, and the public to the withdrawal of the statements “so that sufferers who could advantage from statins are not wrongly deterred from starting or continuing treatment simply because of exaggerated worries over side results”.
She added that their withdrawal raised the query of whether the total articles should be pulled, saying: “Nonetheless, as the editor accountable for publishing the articles or blog posts, I have a vested interest in not retracting them unless of course the situation of performing so is entirely clear.
“So I have decided the right point to do is to pass this choice to an independent panel.”
She extra: “Meanwhile, the BMJ will proceed to debate the important questions raised in the two these articles: whether the use of statins ought to be extended to a vastly wider population of folks at minimal threat of cardiovascular disease and the role of saturated fat in heart ailment.”
Statins are at the moment provided to as several as seven million individuals in the United kingdom who have a 20 per cent danger of establishing cardiovascular condition inside of 10 years.
The National Institute for Overall health and Care Excellence (Nice) known as for the NHS to widen this to cover people with just a ten per cent chance following a examine by Professor Rory Collins and a staff at Oxford University.
Prof Collins criticised the papers by Dr Abramson and Dr Malhotra in March, saying they were misleading. It was he who requested the papers be withdrawn, the BMJ explained.
The independent panel will be chaired by Iona Heath, a former chairwoman of the Royal College of General Practitioners and a member of the BMJ’s ethics committee.
The journal mentioned tips from the Global Committee on Publication Ethics state that journals need to contemplate retracting a publication if there is “clear evidence that the findings are unreliable, either as a consequence of misconduct or sincere error”.
The BMJ explained Dr Abramson’s paper re-analysed information from the Cholesterol Treatment method Trialists’ (CTT) Collaboration which showed treating individuals with a less than 20 per cent danger of heart ailment with statins made no distinction to the death fee in excess of the following 10 many years.
This finding has not been challenged, but the paper also cited information from a separate “uncontrolled observational study” and “incorrectly concluded” that statin side-effects occur in 18-20 per cent of patients.
The identical blunder was manufactured by Dr Malhotra in the identical edition of the BMJ and it is these statements that have been withdrawn, the journal said.
Dr Godlee added: “The BMJ and the authors of each these articles have now been produced mindful that this figure is incorrect, and corrections have been published withdrawing these statements.”
Statins are a group of medicines that assist reduce rates of lower-density lipoprotein (LDL) cholesterol – so called “negative cholesterol” – in the blood.
Higher-rates of LDL cholesterol are linked to hardening and narrowing of the arteries, which can lead to heart condition, heart attacks and stroke.
Individuals can reduce their danger naturally by consuming a healthier diet plan, reduced in saturated fats, and growing the amount of omega three fatty acids in their diet.
Cardiovascular ailment is the leading lead to of death in England and Wales. In 2010, 1 in 3 folks died from it.
The NHS estimates that statins save 7,000 lives a 12 months in the United kingdom.
Sharing is caring, but must patient information be on the menu? Photograph: Alamy
Revelations of eavesdropping by US and United kingdom spy companies has without a doubt contributed to the general public’s sensitivities over how our personalized info and data might probably be harnessed and employed by people with significantly less than honourable intentions.
It is, as a result, not surprising that programs for the use of healthcare data have caused a public furore in the Uk, the EU and the US.
The Guardian’s Jonathan Freedland lately wrote with concern that “we now believe in no 1 with our data – not even our doctors”, but public mistrust regarding data sharing goes even more than just the Snowden leaks.
Latest incidences of US hackers gaining access to 300,000 data from the University of Maryland, thirty million Americans getting the victim of health care information breaches considering that 2009, and the information of residents of three nursing properties in New York State discovered on a file-sharing web site have all have offered the American public cause to be anxious.
Scepticism in the United kingdom goes additional nonetheless. Care.data, the properly-documented proposals for a medical record information-sharing venture in the United kingdom, was so badly communicated to the public that its launch has been delayed for 6 months.
Meanwhile, the European Commission’s attempt to bring in new information protection laws, launched two many years in the past, has been place on quickly forward since the Snowden revelations brought the importance of privacy problems to the wider public. It has been suggested by Peter Knight of the United kingdom Department of Well being that new EU rules on information protection would make analysis ‘impractical’.
With so a lot focus centered on the hazards of data sharing and how to manage them, it is straightforward to get rid of sight of the huge optimistic impacts sharing our overall health information has had on aspects of overall health, security and well being services good quality.
For illustration, HealthShare, a statewide Australian organisation centered on anonymised well being record information sharing, is helping healthcare pros to rise to the challenge of supporting patient care by way of clinical information exchange.
At the harder finish of the debate, accessibility to hospital information has undoubtedly improved patient security at the very least, if not saved lives. In the United kingdom, mortality statistics have been credited with highlighting issues this kind of as substantial numbers of unexpected deaths at Mid Staffordshire NHS Trust and, a lot more lately, the fact that more patients are very likely to die soon after surgical procedure carried out on or near to the weekend.
Similarly in the US, a information-sharing initiative among a massive group of US hospitals, launched in 1997 by Premier Healthcare Alliance and dubbed Quest, is credited with saving 92,000 lives and $ 9.1bn above 4 and a half many years. The alliance’s very own report found that considerable enhancements between member hospitals had been recorded in contrast with non-members, including on measures of deaths relevant to heart failure, sepsis and stroke.
In Europe, an agreement in 2004 among the Gustave Roussy Institute in France and the MD Anderson Cancer Center at the University of Texas brought about a collaboration that produced research on certain therapies and, in the name of improving cancer therapy, shared the newest experimental and clinical information to find jointly the greatest ways to deal with cancer.
Whilst there is already an availability of gene-level information, the exchange initiative will open up better access for both cancer centres, providing them much more time to find treatments as they will commit much less time duplicating research.
The Kolín-Čáslav health information and exchange network, based mostly in the Czech Republic, is considered a European good practice situation study for the advantages of the electronic overall health record (EHR). The network covers patient information sharing in between two hospitals and personal practice physicians that has delivered improved high quality of care. In accordance to a review of its advancement, efficiency and care have improved consultations, examinations and care selections are greater informed, which has ensured that individuals are not possessing pointless duplicate consultations with medical doctors and are getting quicker remedy.
A current study from PatientsLikeMe, a healthcare analysis platform and social networking web site, found that 94% of American social media consumers, with the suitable anonymity, would share their overall health data to assist physicians increase care. Making certain that they are in a position to do this – and making certain that they are in a position to benefit from the enhancements in care – is just as crucial as guarding their anonymity. In conducting the debate about data share, we need to maintain sight of the fantastic extent to which data sharing boosts health-related and wellness study and care in methods we need to not be expected to dwell with no.
Craig Manson is executive vice-president (global) at Dr Foster Intelligence
Are you a member of our online local community? Join the Healthcare Specialists Network to obtain typical emails and unique gives.
Due to the fact there was a tiny price range, Stunt explains, it was crucial adverts should stand out.
Any sort of cancer is a horrible disease but, fortunately, funding and campaigning has witnessed the survival costs for several kinds of the illness boost tremendously in the last number of decades.
Even so, pancreatic cancer, the UK’s fifth largest killer amid cancers, has been minor acknowledged, poorly understood and chronically underfunded, which goes some way to explaining why survival charges have not enhanced in forty years.
Even though no early detection method exists for the cancer, the crucial to shifting survival figures is early diagnosis. If a patient is diagnosed in time for them to obtain surgical procedure, their chance of survival increases tenfold.
A latest patient survey discovered that far more than 50% of pancreatic cancer sufferers had in no way heard of the ailment before their own diagnosis. We have been established to adjust this lack of awareness and eventually drive earlier diagnosis, which is why we worked with Team Darwin to devise a effective campaign.
Shock factor With a restricted spending budget, it was important that the advert would stand out and provoke thought and initiate discussionamong members of the public, the media and influencers.
This is when Staff Darwin conceived the concept of the “I want I had … ” campaign. Pancreatic cancer sufferers are proven explaining that they wished they had breast, cervical or testicular cancer due to the fact their odds of survival would be greater. It displays the genuine insight of numerous pancreatic cancer patients upon diagnosis, and how it feels to be diagnosed with a illness that leaves you with no hope at all.
As taboo as it may sound, when faced with a 3% possibility of surviving a lot more than 5 years, it is not unreasonable to want for a cancer with a better survival fee. This is specifically how I felt when I was diagnosed with the condition in 2007.
The determination to run this campaign was not taken lightly, and we carried out a honest quantity of research to recognize what the probably reaction was going to be.
We also exposed the campaign to many folks, which includes those who’d been impacted by the cancers pointed out in the campaign, as well as people who’d been affected by pancreatic cancer itself.
The end result was that we knew that once folks understood the copy in the advert, the chance of real offence was very reduced. We also knew that the response created was strong and was for that reason most likely to lodge in people’s memories – thus helping our goals of raising awareness of this terrible condition and its signs and symptoms.
All the adverts characteristic true pancreatic cancer individuals who genuinely truly feel that way. None of them hesitated in taking part in the campaign. What these patients are wishing for are greater odds than those they are dealing with.
While the direct criticisms that we have received are in their hundreds, millions of men and women are now aware of pancreatic cancer who weren’t a week in the past. And they’re now becoming aware of the signs and symptoms. As effectively as a huge improve in views of our signs webpage, we have acquired telephone calls from people wanting to discover out a lot more. The attention this campaign has obtained has also paved the way for a symptoms-awareness campaign that we launched on the London tube this week.
Our aim is to save lives and that is accomplished by early diagnosis, which come from making awareness wherever and whichever way we can.
Ali Stunt is the chief executive of Pancreatic Cancer Action.
For far more updates and opinions on the problems and options facing the voluntary sector, join our network or follow us on Twitter @GdnVoluntary. If you have an thought or a recommendations don’t hesitate to e-mail us on voluntarysectornetwork@theguardian.com.
My mother in law, Alice never attended college as a youthful person. She’s producing up for misplaced time now although. Twice a week she packs a lunch and goes to the local local community college for the Studying In Retirement series of classes. You may uncover your aging parent in class someplace, also. She loves it. There’s Trials of the Century, taught by a retired lawyer. And then there’s Controversial Troubles.
Final week, my husband, Mikol, who is a psychologist, was going to her and he went along to class. The subject of the day was healthcare marijuana. The instructor led the discussion by asking the class, which consisted of about 50 seniors, what their experience was and what their opinions were on using health-related marijuana. The group had many elderly retired experts in it: doctors, attorneys, accountants and other individuals. Some were not formally educated, however it appeared there were a lot of thoughtful folks of all backgrounds contributing to the discussion.
Mikol observed that about half the class shared good private experiences with medical marijuana, singing its praises as a pain reliever, tension reducer, and support for insomniacs. The consensus was that healthcare marijuana is excellent and does not have the side effects of prescription drugs utilized for pain, tension and for sleep, say nothing at all of the dangers and higher cost of prescription pharmaceuticals. People reported currently being “strung out” on opiate soreness medication until finally they began utilizing medical marijuana. They received much better relief and no addiction from marijuana, they stated. Most felt it must be a mainstream treatment, not a single that is in the legal hodgepodge that exists underneath our state and Federal governments.
Health-related marijuana is legal in California, exactly where Alice lives. However the conflict in between Federal law, which nevertheless categorizes marijuana as a Category 1 controlled substance, and CA CA law which enables it for healthcare use, is nevertheless a problem. Those in favor of healthcare marijuana in the class argued that our society legalizes the two smoking tobacco and making use of alcohol, which can do a wonderful deal of harm to many. They expressed dismay that smoking tobacco is legal and is usually dangerous, although marijuana, which can be taken in edible merchandise, is unlawful beneath Federal law, but is far significantly less probably to trigger any harm. Now that strains of marijuana for health-related use are offered without having the lively ingredient, THC, that causes the “high” or alteration in consciousness, there was no objection to its use amid individuals in the class. Their discussion was that you can get the benefit of the medicinal results and you can choose a kind without having THC, so there is each cause to allow it and end prosecuting its use.
1 of the leaders of the class was a retired D.A. He described his own struggle with abdominal soreness from Crohn’s Illness which was so tough to control until he experimented with health-related marijuana. He got relief from his symptoms and will continue to use it despite the conflict with Federal law.
Alice finds the lessons quite stimulating and enjoys the discussion. As it occurs, she has been making an attempt out health-related marijuana in edible (droplet) type for soreness in her knees, which can make it tough to stand and get up from a chair or bed. This is a new energy to address her knee difficulty. Previously, she has tried every other attainable kind of treatment method for her knees with no substantial improvement. So far, she says it’s helping. We’ll preserve you posted. And no doubt, she will participate in the following class discussion on this topic.
Right up until following time, Carolyn Rosenblatt AgingParents.com
